

# **Social Anxiety Disorder (aka Social Phobia)**

R. Bruce Lydiard PhD, MD

James Jefferson, MD

J.R.T. Davidson, MD

Murray B. Stein, MD

John Greist, MD

David Katzelnick, MD

# Pre-Lecture Exam

## Question 1

1. The lifetime prevalence of social anxiety disorder is approximately:
  - A. 13.1%
  - B. 0.7%
  - C. 3.5%
  - D. 24.9%
  - E. 13.3%

## Question 2

- 2. Which of the statements regarding social anxiety disorder treatment is true?**
- A.** Social anxiety disorder is more common than panic disorder.
  - B.** Social anxiety disorder does not respond to tricyclic antidepressants
  - C.** Buspirone is more effective for social disorder than alprazolam.
  - D.** Women with social anxiety disorder is as disabling as major depression.

## Question 3

- 3. Compared with normals, individuals with social anxiety disorder are more likely to develop all but which condition?**
- A. Alcoholism
  - B. Major Depression
  - C. Antisocial personality
  - D. Panic Disorder
  - E. PTSD

# Question 4

4. Which one of the following statements about comorbidity in social anxiety disorder is not true?
- A. GAD is the most common coexisting psychiatric disorder.
  - B. Social phobia is a risk factor for depression.
  - C. Approximately 25% of patients with social phobia abuse alcohol.
  - D. Generalized social anxiety disorder is more likely to be associated with comorbidity.
  - E. Avoidant personality disorder is the most prevalent Axis II disorder in generalized social anxiety.

## Question 5

- 5. Social anxiety is poorly recognized because:**
- A.** It is unimportant.
  - B.** Sufferers are reluctant to seek attention for it.
  - C.** Sufferers are unaware that it is a treatable condition.
  - D.** Professionals are unaware of it.
  - E.** All of the above.

“The human brain is a wonderful thing. It operates from the moment you’re born, until the first time you get up to make a speech.”

–Howard Goshorn  
( And Toastmasters)



Is she just shy?

Or is it Social Anxiety Disorder?



# Sensitivity to Scrutiny



# **Social Anxiety Disorder**

**Ereuthrophobia**

**Casper, 1842**

**Kontaktneurosen**

**Stockert, 1929**

**Tai-jin-kyofu**

**Morita, 1932**

**Social neurosis**

**Schilder, 1938**

**Social anxiety neurosis**

**Myerson, 1945**

**Social phobia**

**Marks, 1968**

[A man who] “through bashfulness, suspicion and timorousness, will not be seen abroad; ... his hat still in his eyes, he will neither see nor be seen by his goodwill. He dare not come in company for fear he should be misused, disgraced, overshoot himself in gestures or speeches or be sick; he thinks every man observes him.”

A patient of Hippocrates as recounted by Robert Burton. In: Anatomy of Melancholy. 121 p. 272

# DSM-IV: Social Anxiety Disorder

- Fear that performance will prove humiliating or embarrassing
- Not related to other axis I or III disorders
- Exposure to feared situation → anxiety
- Avoidance or distress
- Social or occupational problems or worried about fear
- Knows fear is excessive

# Lifetime And 12-Month Prevalence Of Anxiety Disorders In The NCS

---

Affective Disorders	Lifetime/ 12 mo. (%)	
---------------------	----------------------	--

---

Panic Disorder	3.5	2.3
Agoraphobia without panic	5.3	2.6
<b>Social Phobia</b>	<b>13.3</b>	<b>7.9</b>
Simple Phobia	11.3	8.8
Generalized anxiety disorder	5.1	3.1
Posttraumatic stress disorder	7.6	3.9
<b>Any anxiety disorder</b>	<b>28.7</b>	<b>19.3</b>

---

Kessler et al. *Arch Gen. Psychiatry.* 1994;51:8.

# Prevalence of Social Anxiety Disorder

	Prevalence (%)	
	Lifetime	One-month
<b>Magee et al, 1996</b> <b>General population</b>	<b>13.3</b>	<b>4.5</b>
<b>Schneier et al, 1992</b> <b>General population</b>	<b>2.4</b>	<b>-</b>
<b>Wacker et al, 1992</b> <b>General population</b>	<b>16.0</b>	<b>-</b>
<b>Weiller et al, 1996</b> <b>Primary care</b>	<b>14.4</b>	<b>4.9</b>

All studies based on DSM-III-R diagnosis

# Age at Onset of Social Anxiety Disorder (ECA)



Schneier et al 1992

# Age of onset of social anxiety disorder

	Average age of onset (years)
<b>Magee et al, 1996</b>	<b>16.0</b>
<b>Weiller et al, 1996</b>	<b>15.1</b>
<b>Schneier et al, 1992</b>	<b>15.5</b>
<b>Stein et al, 1990</b>	<b>15.2</b>



# Social Anxiety Disorder Subtypes

- Generalized
  - Almost all domains affected
- Non-generalized
  - One or two social situation--usually public speaking only

# Generalized social anxiety disorder

- The most disabling form of social anxiety disorder (Stein, 1996)
- Highly familial (Mannuzza et al, 1995; Stein et al, 1998)
- High comorbidity
  - with other anxiety and mood disorders
- Chronic condition
  - requires chronic (not 'as required') treatment

# What are the symptoms of social anxiety disorder?

## Physical:

Tachycardia  
Trembling  
Blushing  
Shortness of breath  
Sweating  
Abdominal distress

## Cognitive:

Maladaptive thoughts and beliefs about social situations

## Behavioral:

Freezing  
Avoidance

# Which symptoms do you fear most?

Anxiety about trembling 33%

Anxiety about blushing 12%

Van Vliet et al, 1994

# Feared situations

## Social

- Attending parties, weddings etc
- Conversing in a group
- Speaking on telephone
- Interacting with authority figure (eg teacher or boss)
- Making eye contact
- Ordering food in a restaurant

## Performance

- Public speaking
- Eating in public
- Writing a check
- Using public toilet
- Taking a test
- Trying on clothes in a store
- Speaking up at a meeting

# Precipitating situations

- Being introduced
- Meeting people in authority
- Using the telephone
- Receiving visitors
- Being watched doing something
- Writing in front of others
- Speaking in public

# Cognitive patterns

- Overestimation of scrutiny by others
- Overestimating possible rejection, embarrassment or humiliation
- Misinterpretation of response of others
- Exaggerated response to rejection
- Discounting personal achievements / overemphasizing failures

Taylor and Arnow, 1991

# Key Diagnostic Questions

- Addressing large or talking in small groups?
- Attending social events?
- Being watched closely while doing something?
- Fear of embarrassment?
- Blush ,sweat or tremble easily?
- Bothersome and seen as excessive?



# Characteristics of patients with social anxiety disorder

More likely to:

- Have less than 11 years' education
- Earn a low income
- Never marry
- Have no occupation
- Live with parents


# Course of social anxiety disorder

- Social anxiety is a chronic disorder
  - average duration up to 20 years
  - only 27% of patients recover
- Sufferers are more likely to recover if:
  - they have a higher level of education
  - anxiety started after the age of 11 years
  - there is no comorbid psychiatric disorder


# Complications of Social Anxiety Disorder in Adolescents

- Depression
- Truancy
- Other conduct problems
- Alcohol and other substance abuse

# Progression of Impairment




# Quality of life in patients with social anxiety disorder as assessed with the SF-36 scale



# Social Anxiety Disorder Etiology

- Genetic / familial
- Behavioral inhibition
- Early experiences / parenting
- Ethological
- Cognitive
- Neurobiological
- Traumatic / conditioning

# Genetic / family studies of social anxiety disorder



<sup>1</sup>Kendler et al, 1992; <sup>2</sup>Fyer et al, 1993; <sup>3</sup>Manuzza et al, 1995


# Family / Environment

- Factors that may contribute to the onset of social anxiety disorder:
  - parental predisposition to anxiety
  - parental restriction of children's social engagement
  - transfer of fear and anxiety via observational learning or verbal information transfer




# Increased Right Temporal Lobe Activity During Provoked Social Anxiety

3 Medication Free Social Phobia Patients



A Socially Anxious and non-Socially Anxious Healthy Control



Functional Neuroimaging Research  
Division, Medical University of South  
Carolina, Charleston, SC

BOLD fMRI studies within subjects

$P < 0.001$  for display

## Figure Legend:

These are coronal structural MRI scans from three medication-free subjects with Generalized Social Phobia (GSP), (top row), and two healthy adults without social phobia (bottom row). Superimposed on the structural MRI scans are the brain regions (in color,  $p < 0.001$ ) which had significantly more blood flow while subjects were self-evaluating their performance after a just completed speech in the MRI scanner in front of an audience. Note that in all 3 subjects with GSP, there is increased activity in the right temporal lobe region. This was not seen in one healthy control (bottom right). Interestingly, the other healthy control had social anxiety about their speech and also has increased right temporal lobe activation. These pilot findings are being rigorously addressed in ongoing work.

From the Medical University of South Carolina Functional Neuroimaging Research Group and the Mood and Anxiety Program, Charleston, SC


Lorberbaum JP, George MS, Johnson MR, Emmanuel NP, Book SW, Mintzer O, Morton A, Nahas Z, Bohning DE, Vincent D, Shastri A, Hamner M, Arana GW, Ballenger JC, Lydiard RB. Feasibility of using fMRI in Social Phobics undergoing a Public Speaking Task. Biological Psychiatry 1999; 45:8s, #429

# Delay to Diagnosis

- The nature of social anxiety disorder causes the patient to delay seeking help
- When the patient does consult a doctor, it will often be to seek treatment for the physical symptoms


# Generalized Social Anxiety Disorder

Percent Diagnosed by Physician in Past Year



Katzelnick et al, 1999

# Missed Opportunity for Treatment



# Social anxiety disorder is undertreated

- Only a minority of patients seek professional help
- An estimated 2.4 million sufferers in the US go untreated
- In a French study, a diagnosis of anxiety disorder was made by GPs in only 24% of a sample of patients with social anxiety disorder

# Why Is It Undertreated?

- Lack of information that social anxiety disorder is treatable
- Sufferer's belief that it is 'just part of my personality' or acceptance of shyness as a normal human characteristic
- Trivialization of the problem by family, friends and professionals
- Stigma attached to social anxiety disorder as a mental disorder
- Inherent avoidance of strangers , including professionals

# Untreated Social Anxiety Disorder

- Academic underachievement
- Inability to work, or under-performance at work
- Financial dependence
- Difficulty making and maintaining friendships or relationships
- Extensive and often unnecessary medical examinations
- Development of alcoholism, depression, agoraphobia, or suicidal ideation




# Comorbidity

- Around 80% of patients with social anxiety disorder report at least one other psychiatric disorder
- Typically, social anxiety disorder occurs before the comorbid condition

53% of patients (Magee et al, 1996)


69% of patients (Schneier et al, 1992)

# Common comorbid conditions



Magee et al, 1996

# Lifetime comorbidity in social anxiety disorder



# **Alcoholism in social anxiety disorder**

## **Clinical studies**

	<b>n</b>	<b>Alcoholism (%)</b>
<b>1983 Amies et al</b>	<b>87</b>	<b>20</b>
<b>1986 Thyer &amp; Curtis</b>	<b>42</b>	<b>36.4</b>
<b>1990 Perugi &amp; Savino</b>	<b>25</b>	<b>20.0</b>
<b>1991 Van Amerigen et al</b>	<b>57</b>	<b>28.1</b>
<b>1991 Cardot</b>	<b>35</b>	<b>14.3</b>
<b>1992 Otto et al</b>	<b>30</b>	<b>43.3</b>
<b>1996 Weiller et al</b>	<b>74</b>	<b>23.6</b>

# **Social anxiety disorder in alcoholic patients**

## **Clinical studies**

	<b>n</b>	<b>Social anxiety disorder (%)</b>
<b>1979 Mullaney &amp; Tripett</b>	<b>102</b>	<b>23.5</b>
<b>1984 Stockwell et al</b>	<b>42</b>	<b>57</b>
<b>1984 Bowen et al</b>	<b>48</b>	<b>8.3</b>
<b>1984 Smail et al</b>	<b>60</b>	<b>39</b>
<b>1985 Weiss &amp; Rosenberg</b>	<b>84</b>	<b>2.4</b>
<b>1986 Stravynsky et al</b>	<b>96</b>	<b>7.8</b>
<b>1987 Chambless et al</b>	<b>75</b>	<b>18.7</b>
<b>1988 Ross et al</b>	<b>501</b>	<b>12.0</b>
<b>1990 Servant et al</b>	<b>152</b>	<b>15</b>
<b>1991 Thevos &amp; Latham</b>	<b>33</b>	<b>15</b>
<b>1995 Clark et al</b>	<b>43</b>	<b>20.9</b>
<b>1995 Marra</b>	<b>44</b>	<b>40.9</b>
<b>1996 Driessen et al</b>	<b>100</b>	<b>10.0</b>
<b>1997 Chignon et al</b>	<b>507</b>	<b>20.1</b>

# **Social anxiety disorder - Odds ratio of lifetime comorbidity with alcohol abuse/dependence**

## **Epidemiological studies**

	<b>n</b>	<b>Alcohol abuse / dependence</b>
<b>ECA, 4 sites</b>	<b>10,314</b>	<b>2.2</b>
<b>ECA, North Carolina</b>	<b>3801</b>	<b>2.2</b>
<b>Zürich</b>	<b>591</b>	<b>3.5</b>
<b>NCS</b>	<b>8098</b>	<b>2.2</b>

# Social Anxiety Disorder: Alcohol Abuse and Dependence

Alcohol abuse		Alcohol dependence	
Men	Women	Men	Women
0.97	2.16*	2.04*	2.57*

\*p<0.05


# Risk of suicidality in comorbid social anxiety disorder

	Nil disorder	Pure social anxiety	Social anxiety plus 1 disorder	Social anxiety plus $\geq 2$ disorders	
Lifetime suicide attempts	0.4%	0.0%	2%	21%	p=0.0001
Have you ever wished to die?	1.4%	3.8%	2%	25.3%	p=0.0001
Have you ever thought about death?	11.6%	39.5%	38.1%	60.4%	p=0.0001



# UCSD social phobia in primary care

## Functional impairment



# Key diagnostic questions

- Are you afraid of speaking to large groups?
- Are you afraid of talking in small groups?
- Do you avoid social events?
- Do you fear being watched closely while doing something?
- Are you afraid of embarrassment?
- Do you blush or sweat easily?
- Do any of these bother you?
- Are any of these fears excessive?

# Social Phobia Inventory (SPIN)

## Examples

Not at all 0	A little bit 1	Some- what 2	Very much 3	Extremely 4
--------------------	----------------------	--------------------	-------------------	----------------

1. I am afraid of people  
in authority

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------	--------------------------	--------------------------	--------------------------

7. Sweating in front of  
people causes me distress

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------	--------------------------	--------------------------	--------------------------

9. I avoid activities where  
I am the center of attention

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------	--------------------------	--------------------------	--------------------------

Total (1 - 17) = 0 - 68

# Screening for social anxiety disorder with the SPIN

## AT CUT-OFF OF 19


<b>Sensitivity</b>	<b>72.5%</b>
<b>Specificity</b>	<b>84.3%</b>
<b>PPV</b>	<b>80.7%</b>
<b>NPV</b>	<b>77.1%</b>
<b>Efficiency</b>	<b>78.6%</b>

# Differential Diagnosis

- Panic disorder/ Agoraphobia
- Posttraumatic stress disorder
- Depression-related social avoidance
- Atypical depression
- Schizotypal / schizoid PD
- Avoidant PD
- Body Dysmorphic disorder

# Social anxiety disorder

## Treatment options



# **Social anxiety disorder**

## **Treatment goals**

- Control anxiety and phobic avoidance
- Reduce associated disability
- Treat depression / other comorbid disorders
- Tolerability over long term
- Eventual medication-free status

# Pharmacological management of social anxiety disorder

- Consider initial choice of an SSRI
- Initial dose for 2-4 weeks, then increase if necessary
- Some benefit evident by 2-4 weeks
- If no response by 6-8 weeks, switch to drug of another class or augment
- Consider psychosocial treatments in some circumstances
- Continue pharmacotherapy for at least 1 year



# Social Anxiety Disorder: Pharmacological Treatments


- Monoamine oxidase inhibitors (standard/RIMAs)
- Benzodiazepines
- SSRIs

# Social Anxiety Disorder

## Issues for Pharmacotherapy

- Uneven efficacy across agents
- Range of response
- Subtypes of social anxiety disorder
- Which core features respond?
- Relapse after Rx discontinuation
- Future directions

# Cognitive-Behavior Group Therapy vs Phenelzine Response by Subtype of Social Phobia\*




\*Intent to treat.

Heimberg et al AGP 1998 55: 1133-41.

# Phenelzine vs. CBGT: Different Strengths


- Phenelzine results in greater improvement
- CBGT results in more durable improvement

# MAOI Response in Social Anxiety Disorder




Liebowitz et al, 1992; Gelernter et al, 1991; Versiani et al, 1992

# RIMA Response Rates in Social Anxiety Disorder




Schneier et al, 1998; Noyes et al, 1997; Internatl GP, 1997;  
Lott et al, 1997; Van Vliet et al, 1992; Fahlen et al, 1995

# BZ Response Rates in Social Anxiety Disorder




# SSRI Response Rates in Social Anxiety Disorder





# Venlafaxine XR for SAD

Flexible Dose 75-225 mg/day




\* $P = 0.022$ ; † $P = 0.003$ ; ‡ $P = 0.0002$ .

ITT Population, LOCF Analysis Liebowitz, APA, 2003.

# Sertraline in Social Anxiety Disorder


## Status at Week 12 Endpoint



\*ITT Responder: CGI-I  $\leq 2$ .

# Effect of Fluvoxamine for Social Phobia (Social Anxiety Disorder; SAD)

## Liebowitz Social Anxiety Scale



\*  $P < 0.05$ ; †  $P < 0.01$ .


Subjects: Patients with SAD (n=86).

Method: A 12 week multicenter, double blind, randomized, placebo controlled trial, patients with SAD were treated fluvoxamine 50-300 mg/day or placebo.

Stein MB, et al. *Am J Psychiatry*. 156(5):756-760.1999.


# Future Treatment Options

- Gabapentin



- Clinical Trial Evidence of Efficacy versus Placebo

- Pregabalin



- Trials Ongoing. One positive study vs placebo

# Buspirone for Social Phobia

- Social phobia (DSM-III-R)\*
  - 12-week open label (N=17)
  - Much improved: 47%
  - Dose range: 15-60 mg
- Performance anxiety in musicians\*\*
  - CBT > placebo = buspirone
  - Small sample size

\*Schneier et al. J Clin Psychiatry. 1993 (August)

\*\*Clark & Agras. Am J Psychiatry. 1991 (May)

# Tricyclic Antidepressants


- Open trials with imipramine and clomipramine in heterogeneous patient groups suggestive of efficacy
- Imipramine: Placebo-controlled trial
  - N=41, 8-week trial
  - Mean dose: 149 mg/d
  - Result: imipramine no more effective than placebo

# Other Drug Treatments

- Newer ADs
  - Mirtazepine-limited evidence
- Anticonvulsants
  - gabapentin, pregabalin
- Beta-blockers\*
  - Atenolol, propranolol


\*limited to performance subtype

# Pharmacotherapy improves core aspects of social anxiety disorder in SSRIs






# Pharmacotherapy Improves Negative Cognitions



# Paroxetine Treatment Of Social Anxiety Disorder

## Improvement In Disability (ITT/LOCF)




\*  $P < .001$ ; \*\*  $P = .03$ ; †  $P = .17$ .

These data represent secondary endpoint analyses.

Stein et al. *JAMA*. 1998;280:708.


# QoL in US Study



All *P*-values are significant ( $P < 0.05$ ).

Liebowitz, APA, 2003


# Relapse Prevention: Medication Maintenance



Stein et al, 1996; Davidson et al, 1998;  
Fahlen et al, 1995; Versiani et al, 1996

# Sertraline: Relapse\* Prevention in Social Anxiety Disorder

Proportion of Patients Relapsing During 24 Weeks of DB Treatment



\*Relapse = CGI-S increase  $\geq 2$  from continuation study baseline or discontinuation due to lack of efficacy.  
Walker et al. *J Clin Psychopharm.* 2000.

# Pharmacological Treatment : Current Guidelines

- SSRIs or venlafaxine first-line treatment
- Higher dosing may be necessary
- Benefit often evident by 2-4 weeks
- Maintain dose achieving response
- If no response by 6-8 weeks, switch to second SSRI

# Pharmacological Treatment : Current Guidelines (cont)

- If no response, try another class
- Adjunctive BZ often useful
- Add formal psychosocial treatment
- Continue for at least 1 year after maximum improvement achieved

# CBT Pros and Cons

---

- Advantages

- It works
- It keeps working
- Most people like it
- Time-limited
  - overall low price
- Few side-effects

- Disadvantages

- More work
  - Limited supply
  - May not be covered by insurance
  - Not for everyone
-



# Social Anxiety Disorder


## Psychosocial Treatments

- Exposure
- Cognitive-behavioral
- Social skills


# Cognitive-Behavioral Treatments

- CBT Group setting ( Heimberg et al)
- Social effectiveness training (Turner , Beidel , Cooley-Quille )
- Other treatments (Foa and others)
- Comparative efficacy established

# Response rate at 12 weeks (Intent-to-treat)



# Cumulative relapse: CBT vs Pheneizine



# Long-term Treatment Indications

- Persistent social anxiety symptoms; relapse after stopping prior treatment
- Comorbid conditions
- Early onset / avoidant personality

# Social Anxiety Disorder: Conclusions

- Common and disabling disorder
- Requires prompt diagnosis to prevent long-term disability
- Underdiagnosed and undertreated
- Demands increased awareness from health professionals and the public

# Post Lecture Exam

## Question 1

1. The lifetime prevalence of social anxiety disorder is approximately:
  - A. 13.1%
  - B. 0.7%
  - C. 3.5%
  - D. 24.9%
  - E. 13.3%

## Question 2

- 2. Which of the statements regarding social anxiety disorder treatment is true?**
- A.** Social anxiety disorder is more common than panic disorder.
  - B.** Social anxiety disorder does not respond to tricyclic antidepressants
  - C.** Buspirone is more effective for social disorder than alprazolam.
  - D.** Women with social anxiety disorder is as disabling as major depression.



## Question 3

- 3. Compared with normals, individuals with social anxiety disorder are more likely to develop all but which condition?**
- A. Alcoholism
  - B. Major Depression
  - C. Antisocial personality
  - D. Panic Disorder
  - E. PTSD

## Question 4

4. Which one of the following statements about comorbidity in social anxiety disorder is not true?
- A. GAD is the most common coexisting psychiatric disorder.
  - B. Social phobia is a risk factor for depression.
  - C. Approximately 25% of patients with social phobia abuse alcohol.
  - D. Generalized social anxiety disorder is more likely to be associated with comorbidity.
  - E. Avoidant personality disorder is the most prevalent Axis II disorder in generalized social anxiety.

## Question 5

- 5. Social anxiety is poorly recognized because:**
- A.** It is unimportant.
  - B.** Sufferers are reluctant to seek attention for it.
  - C.** Sufferers are unaware that it is a treatable condition.
  - D.** Professionals are unaware of it.
  - E.** All of the above.

# Answers to Pre & Post Competency Exams

1. A

2. E

3. C

4. A

5. E